We found that GalR1 and GAlR2 relative immunoreactivity (comparing CRC cells vs. normal epithelial cells) did not correlate with the overall survival and clinical-pathological data of CRC patients (Figure 5A and Figure 5B, respectively). This evidence concerns the gene GALR2 and colorectal carcinoma.